Teclistamab

Published

dm+d

Unassigned

New Medicines

Multiple myeloma - relapsed or refractory

Information

New molecular entity
Janssen
Johnson & Johnson

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials

Category

A bispecific antibody targeting CD3 and B cell maturation antigen (BCMA), given by weekly subcutaneous injection.
The incidence in Europe is 4.5-6.0 per 100,000/year with a mortality rate of 4.1 per 100,000/year. It generally affects older people: median age at presentation is 70 years [1]
Multiple myeloma - relapsed or refractory
Subcutaneous